News

CGeneTech: The first domestic original DPP-4 inhibitor, Shengliptin, is "exempted from two into three"

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2019-11-14
  • Views:0

(Summary description)Today is the 13th "United Nations Diabetes Day", and we have good news from B Village Guest: CGeneTech, which focuses on the research and development of new glucose-lowering drugs, announced that its new glucose-lowering drug, DPP-4 inhibitor Shengliptin phosphate, has been officially approved by the National Center for Drug Review, exempting it from Phase II clinical trials and entering Phase III trials directly, which will promote the first domestic This will facilitate the early launch of the first domestic original DPP-4 inhibitor drug for the benefit of Chinese diabetic patients as soon as possible.

CGeneTech: The first domestic original DPP-4 inhibitor, Shengliptin, is "exempted from two into three"

(Summary description)Today is the 13th "United Nations Diabetes Day", and we have good news from B Village Guest: CGeneTech, which focuses on the research and development of new glucose-lowering drugs, announced that its new glucose-lowering drug, DPP-4 inhibitor Shengliptin phosphate, has been officially approved by the National Center for Drug Review, exempting it from Phase II clinical trials and entering Phase III trials directly, which will promote the first domestic This will facilitate the early launch of the first domestic original DPP-4 inhibitor drug for the benefit of Chinese diabetic patients as soon as possible.

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2019-11-14
  • Views:0

Today is the 13th "United Nations Diabetes Day", and we have good news from B Village Guest: CGeneTech, which focuses on the research and development of new glucose-lowering drugs, announced that its new glucose-lowering drug, DPP-4 inhibitor Shengliptin phosphate, has been officially approved by the National Center for Drug Review, exempting it from Phase II clinical trials and entering Phase III trials directly, which will promote the first domestic This will facilitate the early launch of the first domestic original DPP-4 inhibitor drug for the benefit of Chinese diabetic patients as soon as possible.

The theme of the 2019 United Nations Diabetes Day is "Prevent and Control Diabetes, Protect Your Family", advocating healthy lifestyles and regular testing, and the whole society to take action together to pay attention to diabetes. At present, the situation of diabetes prevention and control worldwide is still serious. According to the World Health Organization's statistical forecast, the number of people with diabetes worldwide reached 422 million in 2017. Among them, 114 million people have the disease in China, which is already more than a quarter of the global total. In the foreseeable future (2020-2030), with the aging of the population, the number of people with the disease will increase to different degrees in all regions of the world. The resulting medical costs are also increasing year by year, imposing a heavy financial burden on patients' families and society.

Opening speech and concluding remarks by Prof. Ji Linong

 

CGeneTech (Suzhou, China) Co., Ltd. is an innovative technology company dedicated to the research and development of hypoglycemic drugs. "In 2012 and 2018, Shengliptin was selected as one of the major new drug creation projects in the 12th and 13th Five-Year Plans. The data from a large sample size clinical phase I trial completed this year showed that the efficacy of Centigliptin phosphate in type 2 diabetes is promising, safe and reliable compared with the positive control drug selegiline. At present, Shenggliptin phosphate has received formal approval from the National Center for Drug Review to be exempted from the Phase II clinical trial and enter the Phase III trial directly.


  Recently, in Beijing, where autumn is enchanting in the midst of all the beauty, CGeneTech successfully held a phase III clinical trial investigator meeting on the combination of Shengliptin phosphate tablets and metformin for the treatment of type 2 diabetes, with a total of 116 investigators from 50 large clinical research centers and endocrinology departments across China attending the meeting. The meeting was chaired by Prof. Ji Linong from Peking University People's Hospital, and experts at the meeting conducted in-depth communication and discussion on the details of phase III trial design and clinical implementation. Prof. Zhao Weigang from Peking Union Medical College Hospital and other participating investigators not only highly affirmed the results of the phase I clinical study of Shengliptin phosphate, but also made valuable suggestions for the phase III clinical trial. As the lead PI of this trial, Prof. Lignon Ji not only communicated with the participants at the academic level, but also concluded that the core R&D team of CGeneTech comes from the best chemistry department in China - the chemistry department of Peking University, and Shenggliptin phosphate has been continuously supported by the key innovative drugs at the national level. As the first home-made original DPP-4 inhibitor, Shengliptin will certainly have a great impact on the domestic diabetes drug market, benefiting the general public. Meanwhile, Prof. Ji also took this opportunity to invite more experts in the field of diabetes to attend another Investigator Conference on the Phase III trial of Shengliptin phosphate monotherapy for type 2 diabetes to be held in Beijing on the morning of December 19, 2019.

 

Group photo of all participating researchers

 

Ding Torping, the chairman of CGeneTech, said he expects that new and good drugs such as Shengliptin phosphate will come into the lives of diabetic patients as soon as possible to better help them. The road to drug creation is difficult, technology is the first. Under the prosperous times, the country will be safe and secure.

Brainstorming

Brainstorming | Exploring the Ocean of Stars through Metabolism

With the advancement of the Healthy China 2030 Plan, chronic disease drugs have become a focus of pharmaceutical research and development. Among them, the development of cardiovascular, lipid-lowering, and hypoglycemic and weight loss drugs has become a hot track in the industry. Recently, R&D clients and Haomai Technology held a "brainstorming session" in Zhuhai, focusing on clinical needs, industry trends, and the latest drug development trends in the field of metabolic diseases. Dr. Yu Qiang, founder and CEO of Shengshi Taike, attended the conference and explored the vast universe of chronic disease drugs with guests starting from metabolism.
2024-05-28
Shengshi

Shengshi Taike has once again been listed on the "Top 50 Most Influential Medical and Health Enterprises in China" list

Recently, CHC Medical Consulting and CITIC Securities officially released the "2023 China Healthcare Industry Investment and Financing Honor List". As an innovative pharmaceutical company in the commercialization stage, Shengshi Taike has once again been listed in this category and won the honor of being one of the top 50 most influential medical and health enterprises in China in 2023.
2024-05-17

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO